Oncotarget

Vol 11, No 44

November 3, 2020

View Archive »

Order a Reprint

About The Cover

The cover for issue 44 of Oncotarget features Figure 1, "Schematic diagram of the human IGF2 gene structure," by Radhakrishnan, et al.

Table of Contents

Research Perspectives

MEK inhibitors in non-V600 BRAF mutations and fusions

MEK inhibitors in non-V600 BRAF mutations and fusions

https://doi.org/10.18632/oncotarget.27788

Douglas B. Johnson, Caroline A. Nebhan,  and Marcus S. Noel
3900-3903
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Research Papers

Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells

Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells

https://doi.org/10.18632/oncotarget.27655

Vinodh Kumar Radhakrishnan, Kameswaran Ravichandran, Chibuzo Eke, Amanda Ortiz-Vicil, Qianwei Tan, Marino De León,  and Daisy D. De León
3904-3920
Abstract  |  PDF  |  Full Text  |  How to cite  |  Press Release  |  Podcast  |  Order a Reprint

MEK is a promising target in the basal subtype of bladder cancer

MEK is a promising target in the basal subtype of bladder cancer

https://doi.org/10.18632/oncotarget.27767

Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver,  and Matthew B. Soellner
3921-3932
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells

Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells

https://doi.org/10.18632/oncotarget.27782

Noymi Yam, Jason Levin, Zhengzheng Bao, Wubin Qian,  and Victor A. Levin
3933-3942
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

https://doi.org/10.18632/oncotarget.27769

Robert A. Kazmierczak, Bakul Dhagat-Mehta, Elke Gulden, Li Lee, Lixin Ma, Clintin P. Davis-Stober, Austen A. Barnett,  and Yves C. Chabu
3943-3958
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Video Interview  |  Order a Reprint

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

https://doi.org/10.18632/oncotarget.27784

Geraldine O'Sullivan Coyne, Shivaani Kummar, Robert S. Meehan, Khanh Do, Jerry M. Collins, Larry Anderson, Kazusa Ishii, Naoko Takebe, Jennifer Zlott, Lamin Juwara, Richard Piekarz, Howard Streicher, Elad Sharon, Larry Rubinstein, Andrea Regier Voth, Jay Lozier, Angie B. Dull, Deborah Wilsker, Toshinori Hinoue, Peter W. Laird, Katherine V. Ferry-Galow, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow,  and Alice P. Chen
3959-3971
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors

Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors

https://doi.org/10.18632/oncotarget.27772

Michael R. Mortensen, Jacqueline Mock, Marco Bertolini, Marco Stringhini, Marco Catalano,  and Dario Neri
3972-3983
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma

https://doi.org/10.18632/oncotarget.27775

Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada,  and Kiyoshi Ando
3984-3997
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections

Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections

https://doi.org/10.18632/oncotarget.27787

Uwe Möginger, Niels Marcussen,  and Ole N. Jensen
3998-4015
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

https://doi.org/10.18632/oncotarget.27790

Michael E. Clark, Helen Rizos, Michelle R. Pereira, Ashleigh C. McEvoy, Gabriela Marsavela, Leslie Calapre, Katie Meehan, Olivia Ruhen, Muhammad A. Khattak, Tarek M. Meniawy, Georgina V. Long, Matteo S. Carlino, Alexander M. Menzies, Michael Millward, Melanie Ziman,  and Elin S. Gray
4016-4027
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11–Rad50–Nbs1 complex in the repair of cisplatin-induced DNA cross-links

Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11–Rad50–Nbs1 complex in the repair of cisplatin-induced DNA cross-links

https://doi.org/10.18632/oncotarget.27777

Sanjeev Pasadi,  and Kalappa Muniyappa
4028-4044
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Reviews

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

https://doi.org/10.18632/oncotarget.27785

Niraj Lodhi, Moe Tun, Poonam Nagpal, Arati A. Inamdar, Nehad M. Ayoub, Noor Siyam, Lucia Oton-Gonzalez, Angela Gerona, Dainelle Morris, Rana Sandhu,  and Kwangsun Stephen Suh
4045-4073
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Corrections

Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling

Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling

https://doi.org/10.18632/oncotarget.27779

Bridgette F. Peake, Siobhan M. Eze, Lily Yang, Robert C. Castellino,  and Rita Nahta
4074-4075
Correction  |  PDF  |  How to cite


Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC